9989.HK Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 10:08):

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally...

Stats
Dagens volum	1.25M
Gjennomsnittsvolum	500 237
Markedsverdi	13.06B
EPS	HKD0.0135 ( 2023-09-30 )
Last Dividend	HKD0.112 ( 2023-05-24 )
Next Dividend	HKD0 ( N/A )
P/E	-5.47
ATR14	HKD0.00700 (0.22%)

Volum Korrelasjon

Lang: 0.04 (neutral)

Kort: 0.54 (weak)

Signal:(29.331) Neutral

Shenzhen Hepalink Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Shenzhen Hepalink Korrelasjon - Valuta/Råvare

-0.74
( moderate negative )

-0.85
( strong negative )

0.00
( neutral )

-0.83
( strong negative )

0.00
( neutral )

0.82
( strong )

Shenzhen Hepalink Økonomi

Annual	2023
Omsetning:	HKD5.45B
Bruttogevinst:	HKD1.80B (33.06 %)
EPS:	HKD-0.530

FY	2023
Omsetning:	HKD5.45B
Bruttogevinst:	HKD1.80B (33.06 %)
EPS:	HKD-0.530

FY	2022
Omsetning:	HKD7.16B
Bruttogevinst:	HKD2.33B (32.61 %)
EPS:	HKD0.500

FY	2021
Omsetning:	HKD6.37B
Bruttogevinst:	HKD2.03B (31.94 %)
EPS:	HKD0.180

Financial Reports:

No articles found.

Shenzhen Hepalink Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.112 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Shenzhen Hepalink Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 3.30 - low (9.79%) | Divividend Growth Potential Score: 3.76 - Decrease likely (24.71%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.180	2021-05-28
Last Dividend	HKD0.112	2023-05-24
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	HKD0.333	--
Avg. Dividend % Per Year	0.00%	--
Score	1.59	--
Div. Sustainability Score	3.30
Div.Growth Potential Score	3.76
Div. Directional Score	3.53	--

Next Divdend (Est)
(2025-03-31)

HKD0.183 Estimate 3.06 %

Dividend Stability

0.24 Very Poor

Dividend Score

1.59

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
6099.HK	Ex Dividend Junior	2023-07-14	Annually	0.00%
1848.HK	Ex Dividend Junior	2023-09-07	Semi-Annually	0.00%
0874.HK	Ex Dividend Knight	2023-06-14	Annually	0.00%
0023.HK	Ex Dividend Knight	2023-09-07	Semi-Annually	0.00%
2660.HK	Ex Dividend Knight	2023-06-30	Annually	0.00%
1425.HK	Ex Dividend Junior	2023-06-16	Annually	0.00%
0512.HK	Ex Dividend Knight	2023-06-09	Annually	0.00%
6866.HK	Ex Dividend Junior	2023-07-21	Sporadic	0.00%
1970.HK	Ex Dividend Knight	2023-06-09	Semi-Annually	0.00%
0998.HK	Ex Dividend Junior	2023-06-26	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.144	1.500	-2.88	-4.32	[0 - 0.5]
returnOnAssetsTTM	-0.0408	1.200	-1.360	-1.631	[0 - 0.3]
returnOnEquityTTM	-0.0638	1.500	-1.820	-2.73	[0.1 - 1]
payoutRatioTTM	-0.544	-1.000	-5.44	5.44	[0 - 1]
currentRatioTTM	2.13	0.800	4.37	3.49	[1 - 3]
quickRatioTTM	0.756	0.800	-0.256	-0.205	[0.8 - 2.5]
cashRatioTTM	0.371	1.500	9.05	10.00	[0.2 - 2]
debtRatioTTM	0.290	-1.500	5.17	-7.76	[0 - 0.6]
interestCoverageTTM	-3.86	1.000	-2.54	-2.54	[3 - 30]
operatingCashFlowPerShareTTM	0.462	2.00	9.85	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.159	2.00	9.92	10.00	[0 - 20]
debtEquityRatioTTM	0.467	-1.500	8.13	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.331	1.000	7.82	7.82	[0.2 - 0.8]
operatingProfitMarginTTM	-0.158	1.000	-5.16	-5.16	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.122	1.000	-0.433	-0.433	[0.2 - 2]
assetTurnoverTTM	0.284	0.800	-1.443	-1.154	[0.5 - 2]
Total Score				3.30

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-5.50	1.000	-0.656	0	[1 - 100]
returnOnEquityTTM	-0.0638	2.50	-1.170	-2.73	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.159	2.00	9.95	10.00	[0 - 30]
dividendYielPercentageTTM	3.82	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.462	2.00	9.85	10.00	[0 - 30]
payoutRatioTTM	-0.544	1.500	-5.44	5.44	[0 - 1]
pegRatioTTM	0.561	1.500	9.59	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.125	1.000	9.38	0	[0.1 - 0.5]
Total Score				3.76

Shenzhen Hepalink

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.